JAPAN > India based UPL group is set to acquire Arysta LifeScience for $4.2 billion

upl logo

India based UPL group is set to acquire Arysta LifeScience for $4.2 billion which will enhance UPL’s local farming solutions and synergies to benefit operations in international markets. Arysta LifeScience is the farm pesticides business of investor Bill Ackman’s Platform Specialty Products. The deal is one of the largest outbound deals by an Indian company till date.

Arysta LifeScience is a global provider of innovative crop protection solutions which includes BioSolutions and Seed Treatment. With the acquisition of Arysta LifeScience, UPL will be a differentiated product portfolio global crop protection company. UPL will also benefit from a variety of patented products through the acquisition as well as various collaboration and partnerships and in house R&D capabilities.

India’s National Center for Agricultural Economics and Policy Research aims to boost food grain production by 1.3% annually to 280 million tons by 2020.

About UPL Group

Headquartered in India, UPL Group manufactures and markets agro-chemicals, industrial chemicals, chemical intermediates, and specialty chemicals in India, Europe, North America, Latin America, and internationally while operating in two segments namely Agro Activity and Non- Agro Activity. UPL was founded in 1969 and it employs around 7,435 employees globally.

About Arysta LifeScience

Founded in 2001, Arysta LifeScience Corporation develops, markets, and distributes agro-chemical solutions offering insecticides, fungicides, herbicides, bio-stimulants, and value-added nutrients. Arysta LifeScience Corporation is a subsidiary of Platform Specialty Products Corporation. Arysta LifeScience is headquartered in Japan.

Reference:

  • https://www.livemint.com/Companies/7yZN8Ml7cHLshs8SG6eBhM/UPL-set-to-acquire-Arysta-LifeScience-for-over-4-billion.html
  • https://economictimes.indiatimes.com/markets/stocks/news/upl-acquires-arysta-lifescience-in-4-2-billion-cash-deal/articleshow/65073004.cms
  • https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=20376936
  • https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=3199074